An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Trial ID or NCT#
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma
- - For Dose Escalation: - Subjects with any previously treated advanced (metastatic or refractory) solid tumor type and B-cell non-Hodgkin lymphoma - For Cohort Expansion: - Subjects must have a previously treated advanced solid tumor or B cell non-Hodgkin's lymphoma to be eligible - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - For certain subjects, willing and able to provide pre-treatment and on-treatment fresh tumor biopsy - Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men
- - Known central nervous system metastases or central nervous system as the only source of disease - Other concomitant malignancies (with some exceptions per protocol) - Active, known or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - History of hepatitis (B or C) - History of active or latent tuberculosis
Contact us to find out if this trial is right for you.
View on ClinicalTrials.gov